Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -48.43% is 55% above its 5-year average of -106.63%, near the high end of its 5-year range (-361.39%–-33.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 14.53% above its 12-month average of -56.67%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -48.43%.
RETURN ON EQUITY (ROE)
-48.43%
RETURN ON EQUITY (ROE) AVG TTM
-56.67%
RETURN ON EQUITY (ROE) AVG 3Y
-84.34%
RETURN ON EQUITY (ROE) AVG 5Y
-106.63%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.53%
CURRENT VS 3Y AVG
+42.57%
CURRENT VS 5Y AVG
+54.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 491 covered companies
CURRENT VS SECTOR MEDIAN
-25.64%
vs the sector median at left
Immunome, Inc.
Market Cap
$1.99B
Return on Equity (ROE)
-48.43%
TTM Avg
-56.67%
3Y Avg
-84.34%
5Y Avg
-106.63%
Market Cap
$2.02B
Return on Equity (ROE)
-13.09%
TTM Avg
-10.89%
3Y Avg
-18.29%
5Y Avg
-19.41%
Market Cap
$2.00B
Return on Equity (ROE)
51.09%
TTM Avg
25.46%
3Y Avg
0.90%
5Y Avg
-9.89%
Market Cap
$2.02B
Return on Equity (ROE)
16.36%
TTM Avg
13.19%
3Y Avg
3.41%
5Y Avg
-4.94%
Market Cap
$2.02B
Return on Equity (ROE)
-63.45%
TTM Avg
-58.44%
3Y Avg
-22.42%
5Y Avg
15.04%
Market Cap
$1.94B
Return on Equity (ROE)
-179.99%
TTM Avg
-188.10%
3Y Avg
28.98%
5Y Avg
-2.67%
Market Cap
$2.03B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
Market Cap
$2.03B
Return on Equity (ROE)
N/A
TTM Avg
-101.38%
3Y Avg
-17.29%
5Y Avg
175.33%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunome, Inc. (IMNM) | $1.99B | -48.43% | -56.67% | -84.34% | -106.63% |
| AxoGen, Inc. (AXGN)vs › | $2.02B | -13.09% | -10.89% | -18.29% | -19.41% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.00B | 51.09% | 25.46% | 0.90% | -9.89% |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.02B | 16.36% | 13.19% | 3.41% | -4.94% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.02B | -63.45% | -58.44% | -22.42% | 15.04% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.94B | -179.99% | -188.10% | 28.98% | -2.67% |
| Azenta, Inc. (AZTA)vs › | $2.03B | -8.14% | -6.28% | -6.47% | -2.03% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | N/A | -101.38% | -17.29% | 175.33% |
| Alvotech (ALVO)vs › | $2.07B | N/A | 23.18% | 49.13% | 48.50% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 12.01% | -4.52% | -16.89% | -11.36% |
ROE
-48.4%
ROA
-45.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -48.43% |
| 2026-03-31 | -38.15% |
| 2025-12-31 | -33.48% |
| 2025-09-30 | -84.40% |
| 2025-06-30 | -78.87% |
| 2025-03-31 | -66.78% |
| 2024-12-31 | -161.71% |
| 2024-09-30 | -142.08% |
| 2024-06-30 | -103.45% |
| 2024-03-31 | -81.25% |
| 2023-12-31 | -89.09% |
| 2023-09-30 | -361.39% |
| 2023-06-30 | -280.00% |
| 2023-03-31 | -212.91% |
| 2022-12-31 | -221.56% |
| 2022-09-30 | -160.12% |
| 2022-06-30 | -119.39% |
| 2022-03-31 | -85.72% |
| 2021-12-31 | -51.28% |
| 2021-09-30 | -38.20% |
| 2021-06-30 | -35.62% |
| 2021-03-31 | -50.31% |
| 2020-12-31 | -43.14% |
| 2020-06-30 | -121.60% |
| 2020-03-31 | -328.69% |
